Piper Sandler started coverage on shares of Tectonic Therapeutic (NASDAQ:TECX – Free Report) in a report issued on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $76.00 target price on the stock.
Separately, TD Cowen assumed coverage on shares of Tectonic Therapeutic in a research report on Monday. They set a buy rating for the company.
Read Our Latest Stock Analysis on TECX
Tectonic Therapeutic Stock Performance
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter.
About Tectonic Therapeutic
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
Read More
- Five stocks we like better than Tectonic Therapeutic
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Stock Splits, Do They Really Impact Investors?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
